Harnessing Lipid Polymer Hybrid Nanoparticles for Enhanced Oral Bioavailability of Thymoquinone: In Vitro and In Vivo Assessments

• Published in: Polymers Vol. 14; no. 18; p. 3705
• Main Authors: Imam, Syed Sarim, Gilani, Sadaf Jamal, Bin Jumah, May Nasser, Rizwanullah, Md, Zafar, Ameeduzzafar, Ahmed, Mohammed Muqtader, Alshehri, Sultan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 06-09-2022; MDPI
• Subjects: Analysis; Bioavailability; Biocompatibility; Breast cancer; Chitosan; cytotoxicity; Design optimization; Drug delivery systems; Entrapment; Intestine; lipid-polymer hybrid nanoparticles; Lipids; Nanoparticles; Natural polymers; oral bioavailability; Phytochemicals; Polydispersity; Polymers; Small intestine; Storage stability; Sustained release; thymoquinone; Toxicity; Variance analysis; Zeta potential; Saudi Arabia; India; Mumbai India; United Kingdom > UK; United States > US; thymoquinone; breast cancer; lipid-polymer hybrid nanoparticles; oral bioavailability; cytotoxicity
• ISSN: 2073-4360; 2073-4360
• DOI: 10.3390/polym14183705

The clinical application of phytochemicals such as thymoquinone (THQ) is restricted due to their limited aqueous solubility and oral bioavailability. Developing mucoadhesive nanocarriers to deliver these natural compounds might provide new hope to enhance their oral bioavailability. Herein, this investigation aimed to develop THQ-loaded lipid-polymer hybrid nanoparticles (THQ-LPHNPs) based on natural polymer chitosan. THQ-LPHNPs were fabricated by the nanoprecipitation technique and optimized by the 3-factor 3-level Box−Behnken design. The optimized LPHNPs represented excellent properties for ideal THQ delivery for oral administration. The optimized THQ-LPHNPs revealed the particles size (PS), polydispersity index (PDI), entrapment efficiency (%EE), and zeta potential (ZP) of <200 nm, <0.25, >85%, and >25 mV, respectively. THQ-LPHNPs represented excellent stability in the gastrointestinal milieu and storage stability in different environmental conditions. THQ-LPHNPs represented almost similar release profiles in both gastric as well as intestinal media with the initial fast release for 4 h and after that a sustained release up to 48 h. Further, the optimized THQ-LPHNPs represent excellent mucin binding efficiency (>70%). Cytotoxicity study revealed much better anti-breast cancer activity of THQ-LPHNPs compared with free THQ against MDA-MB-231 and MCF-7 breast cancer cells. Moreover, ex vivo experiments revealed more than three times higher permeation from the intestine after THQ-LPHNPs administration compared to the conventional THQ suspension. Furthermore, the THQ-LPHNPs showed 4.74-fold enhanced bioavailability after oral administration in comparison with the conventional THQ suspension. Therefore, from the above outcomes, mucoadhesive LPHNPs might be suitable nano-scale carriers for enhanced oral bioavailability and therapeutic efficacy of highly lipophilic phytochemicals such as THQ.